Clinical and economic impact of inhaled corticosteroid withdrawal in Spanish COPD patients treated with triple therapy

V. Neches (Madrid, Spain), L. Vallejo-Aparicio (Madrid, Spain), A. Ismaila (Collegeville, United States of America), A. Sicras-Mainar (Barcelona, Spain), A. Sicras-Navarro (Barcelona, Spain), C. González (Valencia, Spain), R. Cuervo (Madrid, Spain), S. Shukla (Collegeville, United States of America), M. Garcia-Peñuela (Madrid, Spain)

Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies
Session: Inhaled treatments for COPD: clinical trials and real-world studies
Session type: E-poster
Number: 800

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
V. Neches (Madrid, Spain), L. Vallejo-Aparicio (Madrid, Spain), A. Ismaila (Collegeville, United States of America), A. Sicras-Mainar (Barcelona, Spain), A. Sicras-Navarro (Barcelona, Spain), C. González (Valencia, Spain), R. Cuervo (Madrid, Spain), S. Shukla (Collegeville, United States of America), M. Garcia-Peñuela (Madrid, Spain). Clinical and economic impact of inhaled corticosteroid withdrawal in Spanish COPD patients treated with triple therapy. 800

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Discontinuation of inhaled corticosteroid treatment in patients with COPD diagnosed in general practice
Source: Eur Respir J 2002; 20: Suppl. 38, 212s
Year: 2002

Comparative effectiveness of two different doses of inhaled corticosteroid in triple therapy on exacerbations in patients with severe COPD: a real-world study
Source: Virtual Congress 2021 – Therapies for respiratory diseases in primary care and COVID - 19
Year: 2021


Effect of ICS withdrawal on COPD exacerbations in patients on triple therapy at baseline
Source: International Congress 2018 – COPD management
Year: 2018


Osteoporosis in patients with long-term inhaled corticosteroids treatment
Source: Eur Respir J 2007; 30: Suppl. 51, 613s
Year: 2007

Cardiovascular safety of long-term therapy with combination bronchodilator in patients with stable COPD
Source: Eur Respir J 2004; 24: Suppl. 48, 290s
Year: 2004

Economic evaluation of the impact of exacerbation frequency in COPD patients treated with single-inhaler triple therapy in Spain: The IMPACT trial
Source: Virtual Congress 2020 – Pharmacological management of COPD
Year: 2020


Patients with moderate asthma symptoms may benefit from short-term inhaled corticosteroid monotherapy
Source: Eur Respir J 2007; 30: Suppl. 51, 615s
Year: 2007

Characteristics of COPD patients treated with inhaled corticosteroid in primary care
Source: International Congress 2018 – Biomarkers for evaluating COPD
Year: 2018

Predictors of inhaled corticosteroid therapy in COPD alone compared to COPD with concomitant asthma managed in primary care
Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD
Year: 2019

Evaluating the efficacy of chronic therapy with tiotropium in COPD through discontinuation of treatment
Source: Eur Respir J 2002; 20: Suppl. 38, 245s
Year: 2002

The effect of combined β2-agonist and anticholinergic inhaled therapy in patients with COPD
Source: Eur Respir J 2004; 24: Suppl. 48, 341s
Year: 2004

Cost consequences of tiotropium plus existing therapy versus existing therapy alone following one year of treatment in patients with COPD
Source: Eur Respir J 2001; 18: Suppl. 33, 5s
Year: 2001

Efficacy and safety of high-dose inhaled corticosteroids therapy in children with asthma
Source: Annual Congress 2010 - Allergy and risk factors in paediatrics
Year: 2010


The effectiveness of inhaled steroids as first-line therapy in the treatment of newly detected asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 266s
Year: 2001

The effect of smoking on severity of asthma and quality of life in patients treated with inhaled corticosteroids and long-acting b2-agonist (ICS/LABA)
Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD
Year: 2012

Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids
Source: Breathe 2010; 6: 365
Year: 2010

The effects of nebulised bronchodilators and corticosteroids treatment compared with inhaled drug therapy for moderate COPD patients
Source: Eur Respir J 2004; 24: Suppl. 48, 290s
Year: 2004

Economic impact of delayed multiple-inhaler triple therapy initiation in COPD patients
Source: Virtual Congress 2020 – Pharmacological management of COPD
Year: 2020


Impact of inhaled corticosteroid use on outcome in COPD patients hospitalised with pneumonia
Source: Annual Congress 2010 - Aetiology and outcomes of infective exacerbations of COPD
Year: 2010


Asthma control among patients receiving inhaled corticosteroids in general practice in Thailand
Source: Annual Congress 2010 - Questionnaires use and psychological aspects in asthma
Year: 2010